2024-518757-42-00招募中2 期
A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin a10ß1-selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Xintela AB
- 入组人数
- 6
- 试验地点
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Camilla Wennersten
Scientific
Xintela AB
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Comparison of systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept in patients with visual impairment due to diabetic macular edemaVisual impairment due to diabetic macula edemaMedDRA version: 17.0Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersEUCTR2014-001639-35-DEovartis Pharma GmbH40
进行中（未招募）
1 期
Comparison of systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept in patients with neovascular (wet) age-related macular degeneratioVisual impairment due to neovascular AMDMedDRA version: 19.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 100000004853EUCTR2014-001182-27-DEovartis Pharma GmbH40
已完成
不适用
A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers.NL-OMON35929Ablynx NV76
已完成
1 期
Study to test the safety and tolerability of a new drug (DNDI-0690) in healthy subjectsVisceral leishmaniasis, cutaneous leishmaniasisInfections and InfestationsISRCTN14683791Drugs for Neglected Diseases Initiative64
尚未招募
不适用
A single-center, double-blind, randomized, phase I/II dose escalating study to assess the safety, tolerability and immunogenicity of three doses of the therapeutic synthetic long peptide (SLP) vaccine (ISA104) in patients with chronic hepatitis B (cHBV).chronic hepatitis BcHBV10047438NL-OMON51362Erasmus MC, Universitair Medisch Centrum Rotterdam24